MS4A1 and interstitial lung disease: It is worth noting that rituximab, a chimeric antibody specifically targeting CD20, has exhibited effectiveness in treating fibrotic lesions in SSc and has been approved for the management of SSc and SSc-ILD in certain countries (44).